KLK2
ENSG00000167751
Target class
Enzyme
Chromosome
19
- Chemical probe available
- No
- Target name
- KLK2
- Gene name
- Kallikrein related peptidase 2
- Gene symbol
- KLK2
- Protein name
- Kallikrein-2 (EC 3.4.21.35) (Glandular kallikrein-1) (hGK-1) (Tissue kallikrein-2)
- Gene biotype
- Protein coding
- Gene family
- Kallikreins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 1,878.28
- Tissue specificity (Gini)
- 0.98
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:3817
- Protein interaction confidence
- 0.857467
- Protein interaction partners
- 15
- R-HSA-1592389
- R-HSA-381426
- R-HSA-5625886
- End position
- 50880567
- Start position
- 50861568
- Chromosome
- 19
- Strand
- Forward
- Tissue specificity (tau)
- 0.999738
- Expression inequality (Gini)
- 0.979741
Expression in transcripts per million
- Prostate
- 1,878.28
- Testis
- 14.8
- Thyroid
- 6.26
- Cells - EBV-transformed lymphocytes
- 1.27
- Cervix - Endocervix
- 0.34
Expression in transcripts per million
- Prostate1,878.28
- Testis14.8
- Thyroid6.26
- Cells - EBV-transformed lymphocytes1.27
- Cervix - Endocervix0.34
- Fallopian Tube0.27
- Spleen0.26
- Cervix - Ectocervix0.24
- Uterus0.16
- Colon - Transverse0.16
- Small Intestine - Terminal Ileum0.16
- Breast - Mammary Tissue0.15
- Bladder0.13
- Minor Salivary Gland0.13
- Pituitary0.11
- Skin - Not Sun Exposed (Suprapubic)0.11
- Nerve - Tibial0.11
- Adrenal Gland0.1
- Skin - Sun Exposed (Lower leg)0.09
- Ovary0.09
- Brain - Cerebellum0.08
- Esophagus - Mucosa0.08
- Stomach0.08
- Vagina0.07
- Liver0.06
And 29 more, listed on the interactive page.
- GO:0005576
- GO:0070062
Molecular functions
- GO:0004252
Related records
Trials (10)
- A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
- A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
- Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer